<DOC>
	<DOC>NCT00317135</DOC>
	<brief_summary>The purpose of this study is to compare the reactogenicity &amp; safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.</brief_summary>
	<brief_title>Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 &amp; 6 Months Age) After a Birth Dose of Hepatitis B.</brief_title>
	<detailed_description>Randomized study with four groups to receive one of the following vaccination regimens after a dose of hepatitis B vaccine given at birth: - One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologicals' Tritanrix™-HepB (3 different groups) - GSK Biologicals' Tritanrix™-HepB/Hiberix™</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criteria at study entry: Healthy infants aged less than or equal to 3 days of age, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks. Exclusion criteria at study entry: Any confirmed immunodeficient condition, based on medical history &amp; physical examination. A family history of congenital or hereditary immunodeficiency. Major congenital defects or serious chronic illness. History of any neurologic disorders or seizures. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. Acute disease at the time of enrolment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Days</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>